Skip to main content
MGTX logo

MeiraGTx Holdings plc (MGTX) Stock: Price, Forecast & Analyst Target

MeiraGTx Holdings plc (MGTX) — MoonshotScore 63/100 (Fair band), calculated Nov 18, 2026. Price $7.98 (-1.97%), as of the Nov 20, 2026 trading session; market cap $780M.

Educational signal · not a buy or sell recommendation · How to read this

$7.98 −$0.16 (-1.97%) Market Cap $780M

MeiraGTx Holdings plc · MGTX · NASDAQ

MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing treatments for serious diseases, particularly ocular, degenerative, and neurodegenerative conditions. The company leverages its gene therapy platform and research collaborations to advance its pipeline of novel therapies.

Price as of Nov 20, 2026

Key Statistics

63 of 100

MoonshotScore v2 · MeiraGTx Holdings (MGTX)

Fair
Business Quality Elite (97)
Financial Safety Okay (52)
Valuation Fair (74)
Growth Durability Compounding (95)
Momentum Quiet (51)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and elite growth, though the balance sheet is only middling. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Quiet.

  • EPS beat 2 of the last 4 reports
  • Altman Z 3.56 · Piotroski F 5
  • ROE 89.5% · ROA 37.5% · current ratio 4.63

Helping: business quality, an attractive price, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for MGTX (58 recorded, newest six shown)
RecordedScoreBand
63Fair
62Fair
62Fair
63Fair
63Fair
63Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$7.98
Change on the day-1.97%
52-week range$6.62 – $15.35
Market capitalisation$780M—
Price / earnings (trailing)9.95
Shares traded on the day1.01M

Price & events

Other perspectives

Council score for MeiraGTx Holdings (MGTX): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Moderate
Growth Durability Strong
Momentum Neutral

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Moderate
Debt/Equity Neutral
ROE Strong
Gross Margin Strong

Read on: Nov 21, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is MeiraGTx Holdings (MGTX), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. MeiraGTx Holdings plc (MGTX) is listed on NASDAQ. It employs 386 people and is led by Alexandria Forbes. The market values it at $780M.

2 · Latest results

What do the latest results show for MeiraGTx Holdings (MGTX)?

Short answer · as of

Against analyst estimates the company has EPS beat 2 of the last 4 reports.

Quarterly income statement — 3 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$410,000-$51M-$0.62 (diluted)
Q4 FY2025$75M$15M—
Q1 FY2026$293,000-$46M-$0.57 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for MeiraGTx Holdings (MGTX)?

Short answer

The MoonshotScore pillars rate business quality, an attractive price, durable growth as strengths. The distress and quality screens read Altman Z 3.56 · Piotroski F 5. Trailing ratios: ROE 89.5% · ROA 37.5% · current ratio 4.63.

4 · What to check next?

What should you watch next at MeiraGTx Holdings (MGTX)?

Short answer · as of

Current published price targets run low $16.00 · high $26.00 · consensus $21.00 · median $21.00 against a quoted price of $7.98 (as of Nov 20, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does MeiraGTx Holdings compare with its peers?

Short answer

MeiraGTx Holdings's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eton Pharmaceuticals, Inc. (ETON) Same industry, near in market value$60.85 Nov 20, 2026$1.76B98 5-pillar Nov 18, 2026
Nurix Therapeutics, Inc. (NRIX) Same industry, near in market value$12.85 Nov 20, 2026$1.40B97 5-pillar Nov 18, 2026
Innoviva, Inc. (INVA) Same industry, near in market value$18.41 Nov 20, 2026$1.31B96 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.45 Nov 19, 2026$475M91 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$40.09 Nov 20, 2026$755M88 5-pillar Nov 18, 2026
AnaptysBio, Inc. (ANAB) Same industry, near in market value$46.63 Nov 20, 2026$1.39B76 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$11.54 Nov 20, 2026$817M69 5-pillar Nov 18, 2026
LB Pharmaceuticals Inc (LBRX) Same industry, near in market value$38.85 Nov 20, 2026$1.26B69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.19 Nov 20, 2026$540M68 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Named competitor$13.61 Nov 20, 2026$4.78B67 5-pillar Nov 18, 2026
Vor Biopharma, Inc. (VOR) Same industry, near in market value$19.19 Nov 20, 2026$1.18B66 5-pillar Nov 18, 2026
MeiraGTx Holdings (MGTX) — this page$7.98$780M63

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$16.00 – $26.00
Consensus target
$21.00
Median target
$21.00

Consensus record · Captured .

Measured against a quoted price of $7.98 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 20, 2026

Transactions
22
Identified insiders
13
Purchases
0
Sales
6
Other transactions
16

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MGTX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported MGTX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about MeiraGTx Holdings (MGTX)?

Read these with our analysis →

Common Questions About MGTX

These answers are editorial: 1 of these 9 answers is drawn from the MGTX research dossier (written May 7, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for MGTX?

MGTX carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is MGTX a good stock to buy?

Stock Expert AI does not rate MGTX buy, sell or hold. MeiraGTx Holdings plc carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MGTX stock price today?

The last price recorded for MeiraGTx Holdings plc (MGTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the MGTX price target?

The analyst consensus price target for MeiraGTx Holdings plc (MGTX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for MGTX?

The main risks for MeiraGTx Holdings plc include the inherent uncertainties associated with clinical-stage drug development. Clinical trial failures represent a significant risk, as negative data could delay or halt the development of its therapies. Regulatory hurdles, such as delays in approval or rejection of its gene therapy programs, also pose a risk.

What are the key factors to evaluate for MGTX?

MeiraGTx Holdings plc (MGTX) holds a MoonshotScore in the moderate range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Research collaboration with Janssen Pharmaceuticals provides validation of MeiraGTx's technology and potential for future revenue streams. Not financial advice.

How frequently does MGTX data refresh on this page?

MGTX's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MGTX's recent stock price performance?

MeiraGTx Holdings plc (MGTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary gene therapy platform. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MGTX overvalued or undervalued right now?

The trailing P/E of MeiraGTx Holdings plc (MGTX) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 7, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 11 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.